Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Olomorasib with Itraconazole or Carbamazepine in Healthy Adults
NCT05860933Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olomorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and solid tumor (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-Time Curve from Time 0 to Infinity and 1 more. Started May 2023; status: completed.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT05860933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860933.